Watch NTLA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 37, shorts 45
Insiders, 90 days
−$287K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8BP/E —DIV YIELD —FCF YIELD -19.53%REV TTM $59.5M +12.6%NET INCOME −$400MNET CASH —52W 8.04 – 27.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $7.7M | −46.2% | — | −$112.8M | −$106.6M | — | -0.80 | −$83.1M | $1.8M | −$84.9M | Aug 6 |
| Q1 2026 · Mar 31 | $15M | −9.5% | — | −$100.5M | −$96.2M | — | -0.81 | −$117.3M | $79K | −$117.4M | Aug 6 |
| Q4 2025 · Dec 31derived | $23M | +78.8% | — | −$98.7M | −$95.8M | — | -0.82 | −$69.3M | $126K | −$69.4M | Feb 26 |
| Q3 2025 · Sep 30 | $13.8M | +51.3% | — | −$111.5M | −$101.3M | — | -0.92 | −$76.9M | $29K | −$76.9M | Nov 6 |
| Q2 2025 · Jun 30 | $14.2M | +104.8% | — | −$110M | −$101.3M | — | -0.98 | −$99.6M | $239K | −$99.9M | Aug 6 |
| Q1 2025 · Mar 31 | $16.6M | −42.5% | — | −$120.8M | −$114.3M | — | -1.10 | −$148.9M | $735K | −$149.7M | Aug 6 |
| Q4 2024 · Dec 31derived | $12.9M | — | — | −$136.4M | −$128.9M | — | -1.26 | −$85.2M | $981K | −$86.2M | Feb 26 |
| Q3 2024 · Sep 30 | $9.1M | −24.0% | — | −$144.8M | −$135.7M | — | -1.34 | −$84.8M | $1.3M | −$86.1M | Nov 6 |
| Q2 2024 · Jun 30 | $7M | — | — | −$139M | −$147M | — | -1.52 | −$58.2M | $1M | −$59.2M | Nov 6 |
| Q1 2024 · Mar 31 | $28.9M | — | — | −$114M | −$107.4M | — | -1.12 | −$120.7M | $2.5M | −$123.2M | Nov 6 |
| Q4 2023 · Dec 31derived | −$1.9M | — | — | −$139.9M | −$132.2M | — | -1.46 | −$93.1M | $1.5M | −$94.6M | Feb 26 |
| Q3 2023 · Sep 30 | $12M | — | — | −$131.1M | −$122.2M | — | -1.38 | −$101.4M | $4.3M | −$105.7M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $67.7M | — | −$441M | −$412.7M | -609.9% | -3.81 | −$394.7M | $1.1M | −$395.9M | — | — |
| FY2024 · to Dec 31 | $57.9M | — | −$534.3M | −$519M | -896.8% | -5.25 | −$348.9M | $5.8M | −$354.7M | — | — |
| FY2023 · to Dec 31 | $36.3M | — | −$515.3M | −$481.2M | -1326.5% | -5.42 | −$394.1M | $14M | −$408.1M | — | — |
| FY2022 · to Dec 31 | $52.1M | — | −$458.2M | −$474.2M | -909.8% | -6.16 | −$333.3M | $13.6M | −$346.8M | — | — |
| FY2021 · to Dec 31 | $33.1M | 100.0% | −$267.9M | −$267.9M | -810.5% | -3.78 | −$225M | $12.8M | −$237.8M | — | — |
| FY2020 · to Dec 31 | $58M | 100.0% | −$136.6M | −$134.2M | -231.5% | -2.40 | −$49.9M | $3.6M | −$53.5M | — | — |
Every number comes from Intellia Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.